Novo Nordisk has announced plans to commence late-stage (phase 3) clinical trials for amycretin, a dual GLP-1 and amylin receptor agonist designed for weight loss. This program includes both subcutaneous and oral formulations, proceeding after positive phase 2 feedback. Prior studies showed up to 22% mean weight loss over 36 weeks. The phase 3 trials targeting overweight and obese adults are slated to start in early 2026, representing Novo’s continued efforts to bolster its obesity treatment portfolio post-Wegovy.